GH-Axis Peptides
CJC-1295, Sermorelin, Ipamorelin, GHRP-2/6, IGF-1 LR3, MGF, Tesamorelin, HGH and HGH-fragment 176-191. GHRH-receptor agonists, GHSR (ghrelin-receptor) agonists, and IGF-axis reagents for somatotropic-pathway research.
AOD9604
≥99.0%Modified HGH fragment 176–191 (anti-obesity drug candidate)
- CAS
- 221231-10-3
- Vial
- 2 mg–10 mg
CJC-1295 (no DAC)
≥99.0%Modified GRF 1-29 · GHRH analog
- CAS
- 863288-34-0
- Vial
- 2 mg–10 mg
CJC-1295 with DAC
≥99.0%Long-acting GHRH analog with Drug Affinity Complex
- CAS
- 863288-34-0
- Vial
- 2 mg · 5 mg
CJC-1295 + Ipamorelin
≥99.0%GH-axis blend (CJC-1295 no DAC + Ipamorelin)
- CAS
- —
- Vial
- 10 mg
GHRP-2
≥99.0%Growth-hormone-releasing peptide-2 · Pralmorelin
- CAS
- 158861-67-7
- Vial
- 5 mg · 10 mg
GHRP-6
≥99.0%Growth-hormone-releasing peptide-6
- CAS
- 87616-84-0
- Vial
- 5 mg · 10 mg
HGH (Somatropin · Human Growth Hormone)
≥99.0%Recombinant human growth hormone · heavily regulated biological
- CAS
- 12629-01-5
- Vial
- 6 IU–40 IU
16-mer
HGH Fragment 176-191
≥99.0%C-terminal fragment of human growth hormone (176–191)
- CAS
- 66004-57-7
- Vial
- 1 mg–15 mg
IGF-1 LR3
≥99.0%Long-Arg3 IGF-1 (long-acting IGF-1 analog)
- CAS
- 946870-92-4
- Vial
- 100 mcg–2 mg
Ipamorelin
≥99.0%Ghrelin / GHSR pathway GH-release peptide
- CAS
- 170851-70-4
- Vial
- 2 mg–10 mg
MGF (Mechano Growth Factor)
≥99.0%IGF-1 Ec splice-variant peptide
- CAS
- —
- Vial
- 2 mg
29-mer
Sermorelin
≥99.0%GHRH 1-29 fragment
- CAS
- 86168-78-7
- Vial
- 2 mg–10 mg
29-mer
Tesamorelin
≥99.0%GHRH analog · approved for HIV-associated lipodystrophy
- CAS
- 218949-48-5
- Vial
- 2 mg–20 mg